Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review

Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) in 2017. We present 2 patients, a 67-year-old woman with history of PPMS and a 42-year-old woman with RRMS, who wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelsey, Andrew, Casinelli, Gabriella, Tandon, Medha, Sriwastava, Shitiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419566/
https://www.ncbi.nlm.nih.gov/pubmed/34497472
http://dx.doi.org/10.1177/11795735211037785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419566/
https://www.ncbi.nlm.nih.gov/pubmed/34497472
http://dx.doi.org/10.1177/11795735211037785

Ejemplares similares